Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free FEMY Stock Alerts

Femasys (FEMY) Competitors

Femasys logo
$0.40 +0.03 (+7.42%)
Closing price 04:00 PM Eastern
Extended Trading
$0.41 +0.01 (+3.63%)
As of 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

FEMY vs. SLNO, NRXS, SPAI, PYPD, and INO

Should you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Soleno Therapeutics (SLNO), NeurAxis (NRXS), Safe Pro Group (SPAI), PolyPid (PYPD), and Inovio Pharmaceuticals (INO). These companies are all part of the "medical equipment" industry.

How does Femasys compare to Soleno Therapeutics?

Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Soleno Therapeutics has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soleno Therapeutics$190.41M14.35$20.89M$0.23230.09
Femasys$2.29M10.54-$18.63M-$0.50N/A

Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -812.74%. Soleno Therapeutics' return on equity of 5.90% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
Soleno TherapeuticsN/A 5.90% 4.61%
Femasys -812.74%-534.94%-116.29%

Soleno Therapeutics has a beta of -2.23, suggesting that its share price is 323% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.26, suggesting that its share price is 326% less volatile than the S&P 500.

Soleno Therapeutics currently has a consensus target price of $76.67, indicating a potential upside of 44.87%. Femasys has a consensus target price of $5.50, indicating a potential upside of 1,276.72%. Given Femasys' stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than Soleno Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soleno Therapeutics
1 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.15
Femasys
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by insiders. Comparatively, 7.6% of Femasys shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Soleno Therapeutics had 38 more articles in the media than Femasys. MarketBeat recorded 39 mentions for Soleno Therapeutics and 1 mentions for Femasys. Soleno Therapeutics' average media sentiment score of 0.11 beat Femasys' score of 0.00 indicating that Soleno Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Soleno Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
32 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Femasys
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Soleno Therapeutics beats Femasys on 12 of the 16 factors compared between the two stocks.

How does Femasys compare to NeurAxis?

NeurAxis (NASDAQ:NRXS) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

NeurAxis has a net margin of -492.76% compared to Femasys' net margin of -812.74%. NeurAxis' return on equity of 0.00% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
NeurAxis-492.76% N/A -641.25%
Femasys -812.74%-534.94%-116.29%

NeurAxis presently has a consensus price target of $13.00, suggesting a potential upside of 49.60%. Femasys has a consensus price target of $5.50, suggesting a potential upside of 1,276.72%. Given Femasys' higher probable upside, analysts plainly believe Femasys is more favorable than NeurAxis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Femasys
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 15.2% of NeurAxis shares are owned by company insiders. Comparatively, 7.6% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

NeurAxis has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.26, suggesting that its share price is 326% less volatile than the S&P 500.

NeurAxis has higher revenue and earnings than Femasys. NeurAxis is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeurAxis$3.57M28.01-$14.63M-$0.94N/A
Femasys$2.29M10.54-$18.63M-$0.50N/A

In the previous week, NeurAxis had 1 more articles in the media than Femasys. MarketBeat recorded 2 mentions for NeurAxis and 1 mentions for Femasys. NeurAxis' average media sentiment score of 0.55 beat Femasys' score of 0.00 indicating that NeurAxis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NeurAxis
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Femasys
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

NeurAxis beats Femasys on 10 of the 16 factors compared between the two stocks.

How does Femasys compare to Safe Pro Group?

Safe Pro Group (NASDAQ:SPAI) and Femasys (NASDAQ:FEMY) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Safe Pro Group has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.26, suggesting that its stock price is 326% less volatile than the S&P 500.

Femasys has a net margin of -812.74% compared to Safe Pro Group's net margin of -2,359.64%. Safe Pro Group's return on equity of -182.66% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
Safe Pro Group-2,359.64% -182.66% -158.99%
Femasys -812.74%-534.94%-116.29%

Safe Pro Group currently has a consensus price target of $10.00, suggesting a potential upside of 132.56%. Femasys has a consensus price target of $5.50, suggesting a potential upside of 1,276.72%. Given Femasys' higher possible upside, analysts clearly believe Femasys is more favorable than Safe Pro Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Safe Pro Group
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.60
Femasys
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Safe Pro Group has higher earnings, but lower revenue than Femasys. Safe Pro Group is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Safe Pro Group$610K147.26-$14.32M-$0.84N/A
Femasys$2.29M10.54-$18.63M-$0.50N/A

65.3% of Femasys shares are owned by institutional investors. 54.8% of Safe Pro Group shares are owned by company insiders. Comparatively, 7.6% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Safe Pro Group had 4 more articles in the media than Femasys. MarketBeat recorded 5 mentions for Safe Pro Group and 1 mentions for Femasys. Safe Pro Group's average media sentiment score of 0.72 beat Femasys' score of 0.00 indicating that Safe Pro Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Safe Pro Group
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Femasys
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Safe Pro Group and Femasys tied by winning 8 of the 16 factors compared between the two stocks.

How does Femasys compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

26.5% of PolyPid shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 7.6% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Femasys has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolyPidN/AN/A-$34.17M-$2.26N/A
Femasys$2.29M10.54-$18.63M-$0.50N/A

PolyPid has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.26, suggesting that its stock price is 326% less volatile than the S&P 500.

PolyPid has a net margin of 0.00% compared to Femasys' net margin of -812.74%. PolyPid's return on equity of -291.42% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
PolyPidN/A -291.42% -131.82%
Femasys -812.74%-534.94%-116.29%

PolyPid currently has a consensus price target of $12.25, suggesting a potential upside of 172.22%. Femasys has a consensus price target of $5.50, suggesting a potential upside of 1,276.72%. Given Femasys' higher probable upside, analysts clearly believe Femasys is more favorable than PolyPid.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PolyPid
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Femasys
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, PolyPid and PolyPid both had 1 articles in the media. PolyPid's average media sentiment score of 0.85 beat Femasys' score of 0.00 indicating that PolyPid is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PolyPid
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Femasys
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

PolyPid and Femasys tied by winning 7 of the 14 factors compared between the two stocks.

How does Femasys compare to Inovio Pharmaceuticals?

Femasys (NASDAQ:FEMY) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Femasys has a beta of -2.26, suggesting that its share price is 326% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Femasys presently has a consensus price target of $5.50, indicating a potential upside of 1,276.72%. Inovio Pharmaceuticals has a consensus price target of $6.75, indicating a potential upside of 492.11%. Given Femasys' stronger consensus rating and higher possible upside, equities analysts clearly believe Femasys is more favorable than Inovio Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Femasys
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Inovio Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38

Femasys has higher revenue and earnings than Inovio Pharmaceuticals. Femasys is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Femasys$2.29M10.54-$18.63M-$0.50N/A
Inovio Pharmaceuticals$60K1,319.36-$84.95M-$1.68N/A

Inovio Pharmaceuticals has a net margin of 0.00% compared to Femasys' net margin of -812.74%. Inovio Pharmaceuticals' return on equity of -259.70% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
Femasys-812.74% -534.94% -116.29%
Inovio Pharmaceuticals N/A -259.70%-83.46%

65.3% of Femasys shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 7.6% of Femasys shares are owned by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Inovio Pharmaceuticals had 6 more articles in the media than Femasys. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 1 mentions for Femasys. Inovio Pharmaceuticals' average media sentiment score of 0.92 beat Femasys' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Femasys
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inovio Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Inovio Pharmaceuticals beats Femasys on 8 of the 15 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FEMY vs. The Competition

Export
MetricFemasysMED IndustryMedical SectorNASDAQ Exchange
Market Cap$24.13M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-0.8038.8529.0428.47
Price / Sales10.54155.51476.6160.92
Price / CashN/A57.8827.6236.52
Price / Book4.007.039.676.67
Net Income-$18.63M$23.62M$3.55B$332.53M
7 Day Performance7.10%3.68%1.70%2.01%
1 Month Performance-9.04%7.16%5.62%9.19%
1 Year Performance-66.14%67.05%34.41%39.59%

Femasys Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FEMY
Femasys
1.8042 of 5 stars		$0.40
+7.4%		$5.50
+1,276.7%		N/A$24.13M$2.29MN/A30
SLNO
Soleno Therapeutics
4.1867 of 5 stars		$52.78
+0.0%		$76.67
+45.3%		N/A$2.72B$190.40M229.4730
NRXS
NeurAxis
2.969 of 5 stars		$7.80
-4.1%		$13.00
+66.7%		N/A$89.51M$3.57MN/A19
SPAI
Safe Pro Group
3.1222 of 5 stars		$4.22
-1.5%		$10.00
+137.2%		N/A$88.16M$606.68KN/A11
PYPD
PolyPid
2.9679 of 5 stars		$4.45
-2.9%		$12.25
+175.3%		N/A$84.89MN/AN/A80

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:FEMY) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel